(Q35813465)

10 August 2017

1 reference

title

Psoriasis and the new biologic agents: interrupting a T-AP dance (English)

1 reference

10 August 2017

Scott R A Walsh

1

1 reference

10 August 2017

Neil H Shear

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Canadian Medical Association Journal

10 August 2017

1 reference

10 August 2017

170

1 reference

10 August 2017

13

1 reference

10 August 2017

1933-1941

1 reference

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Recombinantly engineered human proteins: transforming the treatment of psoriasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Biologic therapy for psoriasis: the new therapeutic frontier

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Pathophysiology of psoriasis: science behind therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Novel immune-based therapies for psoriasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

The immunologic basis for the treatment of psoriasis with new biologic agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Advances in systemic therapy for psoriasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Phototherapy for psoriasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Pathogenesis of psoriatic arthritis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Finally, CTLA4Ig graduates to the clinic

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=421723

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

24 September 2018

1 reference

12 December 2020

Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study

1 reference

12 December 2020

On the immunopathogenesis of psoriasis

1 reference

12 December 2020

A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis

1 reference

12 December 2020

Nuvion. Protein Design Labs

1 reference

12 December 2020

Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody

1 reference

12 December 2020

Treatment of severe psoriasis with anti-CD25 monoclonal antibodies

1 reference

12 December 2020

Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4

1 reference

12 December 2020

Coping with psoriasis: a guide for counseling patients

1 reference

12 December 2020

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

1 reference

12 December 2020

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

12 December 2020

Identifiers

DOI

10.1503/CMAJ.1031335

1 reference

release_kzw22ujoibgvvnudor5dc35e2e

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kzw22ujoibgvvnudor5dc35e2e

24 November 2022

mapped directly with Wikidata item

1 reference

10 August 2017

PubMed publication ID

15210644

1 reference